Nicole Dale

Pharma Writer, Pharmatica
  • South Africa
  • Joined 2026
3 Followers
7 Following

About

Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.

Areas of Expertise

Published content

    • European Medicinces Agency
    • Pharmacovigilance
    • Pharmacovigilance & Safety
    • Pharma Regulation
    • Pharma Policy
    • Site Inspection
    • AI vendor auditing
    • AI vendor assessment
    • Clinical Research Organisations
    • Electronic Data Capture
    • Data Integrity
    • Pharmaceutical Compliance
    • Audit Findings
    • Regulatory Warning Letters
    • Global Regulatory Affairs
    • Oversight
    • Medical Governance
    • Clinical Trial Sites
    • Clinical Trial Regulation
    • Clinical Data
    • clinical trials
    • Clinical Evidence
    • Adverse Event Monitoring
    • Adverse Events
    • Safety & Toxicology

    What Changes in EMA GVP Module III Revision 2?

    • AI Drug Discovery
    • AI & Machine Learning
    • Machine Learning in Pharma
    • AI Drug Development
    • Drug Discovery
    • Preclinical Development
    • Translational & Pre-clinical Research
    • Translational Science and Biomarkers
    • Nonclinical Development
    • Computational Biology
    • Genetics & Molecular Biology
    • Multiomics
    • Research Informatics
    • Drug Design & Delivery
    • Drug Delivery
    • Biologics
    • Small Molecules
    • Infectious Diseases and Vaccines
    • Pharma Regulation
    • Regulatory & IP
    • Formulation
    • Data Quality
    • Laboratory Quality
    • Oncology
    • Oncology & Radiotherapeutics
    • Neurological Disease
    • Pharmaceutical Manufacturing
    • Analytical Monitoring
    • Pharma Intelligence
    • Biopharmaceutical Manufacturing
    • Manufacturing Technology
    • Safety & Toxicology
    • Pharmacology
    • Non-Animal Testing

    Machine Learning in Drug Discovery: Gains and Data Gaps

    • Pricing and Market Access
    • Market Access & Reimbursement
    • Pharma Policy
    • Health Technology Assessment
    • Drug Pricing
    • Pharma Regulation
    • Global Regulatory Affairs
    • Insurance Reimbursement
    • Oncology
    • Oncology & Radiotherapeutics
    • Peptides and Obesity Treatments
    • Cardiometabolic Diseases
    • Ophthalmology
    • Immunology and Immunotherapy
    • Neurological Disease
    • Advanced Therapies
    • Personalised Healthcare
    • Biologics
    • Cell and Gene Therapy
    • Small Molecules
    • Next-gen Modalities
    • Drug Production
    • Biopharmaceutical Manufacturing
    • Contract Manufacturing (CDMO/CMO)
    • Pharmaceutical Manufacturing
    • Continuous Manufacturing
    • Decentralised Manufacturing
    • Supply Network Strategy
    • Pharma Supply Chains
    • Pharmaceutical Markets
    • Patient Access
    • Patient Care
    • Healthcare Providers
    • Orphan Drugs
    • Rare Diseases
    • Commercial Strategy
    • Commercialisation & Medical Affairs

    CMS Finalises Medicare GLOBE to Rewrite Drug Pricing

    • Clinical Evidence
    • Multinational Trials
    • Clinical Data
    • Clinical Outcomes
    • Clinical Trial Design
    • Clinical Trial Sites
    • clinical trials
    • Decentralised Clinical Trials
    • Clinical Trial Strategy
    • Oncology
    • Oncology & Radiotherapeutics
    • Biostatistics
    • Respiratory Disease
    • Antibody Drug Conjugates
    • Next-gen Modalities
    • Clinical Trial Regulation
    • Global Regulatory Affairs
    • Pharma Regulation
    • Drug Approval
    • Regulatory Approvals
    • Biologics
    • Equity
    • Patient Care
    • patient stratification
    • Patient Registries
    • Patient Centricity and Outcomes
    • Regulatory Pathways
    • Regulatory Strategy

    Ivonescimab Challenges Keytruda Beyond China